Tolerability and Efficacy of Depakote-extended Release in the Elderly

This study has been completed.
Sponsor:
Collaborator:
Abbott
Information provided by (Responsible Party):
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
NCT00318929
First received: April 25, 2006
Last updated: February 21, 2012
Last verified: June 2010
Results First Received: March 31, 2009  
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Elderly
Epilepsy
Seizures
Intervention: Drug: Divalproex Sodium Extended-Release Tablets

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment began April 2006 and completed January 2008. Subjects were seen in an outpatient clinic

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects recruited had either inadequately controlled seizures or were taking Depakote twice a day.

Reporting Groups
  Description
Depakote ER Dosing regimen from 750 to 1250 mg once a day.

Participant Flow:   Overall Study
    Depakote ER  
STARTED     14  
COMPLETED     14  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Depakote ER Dosing regimen from 750 to 1250 mg once a day.

Baseline Measures
    Depakote ER  
Number of Participants  
[units: participants]
  14  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     12  
>=65 years     2  
Age  
[units: years]
Mean ± Standard Deviation
  66.1  ± 9.5  
Gender  
[units: participants]
 
Female     3  
Male     11  
Region of Enrollment  
[units: participants]
 
United States     14  



  Outcome Measures

1.  Primary:   Effectiveness of Medication as Measured by Participation Through the End of the Trial.   [ Time Frame: 24 weeks ]

2.  Secondary:   Patient's Compliance With Once a Day Dosing.   [ Time Frame: 24 weeks ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

3.  Secondary:   Number of Seizures Per Month   [ Time Frame: 24 weeks ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

4.  Secondary:   Change From Baseline as Measured by the Seizure Severity Questionnaire (SSQ)   [ Time Frame: 24 weeks ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Alan R. Towne, MD
Organization: Virginia Commonwealth University
phone: 804-282-9869
e-mail: atowne@mcvh-vcu.edu


No publications provided


Responsible Party: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT00318929     History of Changes
Other Study ID Numbers: VCUHM10204
Study First Received: April 25, 2006
Results First Received: March 31, 2009
Last Updated: February 21, 2012
Health Authority: United States: Institutional Review Board